News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Advertise
Talent Solutions
Post Jobs
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Deals
Ipsen Aims To Raise €400 Million In IPO
November 23, 2005
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
Ipsen, the French pharmaceuticals company, yesterday unveiled plans to raise about €400m ($470m) in an initial public offering, which would reduce the stake of the family of founder Henri Beaufour and raise funds for research.
Twitter
LinkedIn
Facebook
Email
Print
IPO
Europe
MORE ON THIS TOPIC
Artificial intelligence
AstraZeneca bulks up MASH, cardio work in up to $1.5B AI partnership with insitro
October 15, 2026
·
1 min read
·
Annalee Armstrong
Deals
Stoffels strikes up new biotech in return to Galapagos cell therapy mission
October 15, 2026
·
4 min read
·
Annalee Armstrong
Licensing
Gilead snags equity stake in Vir with up to $1.87B deal for three T cell engagers
October 14, 2026
·
1 min read
·
Annalee Armstrong
Obesity
Zealand pens up to $1.2B deal with Generate for AI-designed obesity, metabolic drugs
October 14, 2026
·
3 min read
·
Tristan Manalac
